Connection

Raymond Anton to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Raymond Anton has written about Treatment Outcome.
Raymond Anton
Connection Strength
1.532
Treatment Outcome
  1. The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. J Addict Med. 2022 Jul-Aug 01; 16(4):425-432.
    View in: PubMed
    Score: 0.088
  2. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
    View in: PubMed
    Score: 0.086
  3. Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. J Gen Intern Med. 2021 02; 36(2):404-412.
    View in: PubMed
    Score: 0.082
  4. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
    View in: PubMed
    Score: 0.081
  5. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2020 05 01; 180(5):728-736.
    View in: PubMed
    Score: 0.079
  6. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
    View in: PubMed
    Score: 0.078
  7. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2019 05; 43(5):979-987.
    View in: PubMed
    Score: 0.073
  8. Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res. 2018 Apr; 42(4):751-760.
    View in: PubMed
    Score: 0.068
  9. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcohol Clin Exp Res. 2017 01; 41(1):179-186.
    View in: PubMed
    Score: 0.063
  10. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res. 2012 Nov; 36(11):2000-7.
    View in: PubMed
    Score: 0.045
  11. Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res. 2011 Nov; 35(11):2030-8.
    View in: PubMed
    Score: 0.043
  12. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul; 168(7):709-17.
    View in: PubMed
    Score: 0.042
  13. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009 Aug; 29(4):334-42.
    View in: PubMed
    Score: 0.038
  14. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. J Stud Alcohol Drugs. 2009 Mar; 70(2):186-96.
    View in: PubMed
    Score: 0.036
  15. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008 Jun; 9(6):655-8.
    View in: PubMed
    Score: 0.035
  16. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008 May; 32(5):771-6.
    View in: PubMed
    Score: 0.034
  17. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb; 28(1):5-12.
    View in: PubMed
    Score: 0.034
  18. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb; 65(2):135-44.
    View in: PubMed
    Score: 0.034
  19. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007 Apr; 31(4):596-603.
    View in: PubMed
    Score: 0.032
  20. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug; 25(4):349-57.
    View in: PubMed
    Score: 0.028
  21. Design and analysis of trials of combination therapies. J Stud Alcohol Suppl. 2005 Jul; (15):34-42; discussion 33.
    View in: PubMed
    Score: 0.028
  22. Naltrexone for alcohol dependence: comments on Morris et al. (2001). Addiction. 2001 Dec; 96(12):1855.
    View in: PubMed
    Score: 0.022
  23. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
    View in: PubMed
    Score: 0.022
  24. The Utility of Carbohydrate-Deficient Transferrin in Identifying Chronic Alcohol Users in the Injured Patient: Expanding the Toolkit. J Surg Res. 2021 01; 257:92-100.
    View in: PubMed
    Score: 0.020
  25. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction. 2000 Aug; 95 Suppl 2:S211-7.
    View in: PubMed
    Score: 0.020
  26. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov; 156(11):1758-64.
    View in: PubMed
    Score: 0.019
  27. Contribution of carbohydrate deficient transferrin to gamma glutamyl transpeptidase in evaluating progress of patients in treatment for alcoholism. Alcohol Clin Exp Res. 1999 Jan; 23(1):115-20.
    View in: PubMed
    Score: 0.018
  28. Pharmacotherapy of alcoholism--10 years of progress. Alcohol Clin Exp Res. 1996 Nov; 20(8 Suppl):172A-175A.
    View in: PubMed
    Score: 0.016
  29. New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res. 1996 Oct; 20(7 Suppl):3A-9A.
    View in: PubMed
    Score: 0.015
  30. Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study. Alcohol Clin Exp Res. 1996 Aug; 20(5):841-6.
    View in: PubMed
    Score: 0.015
  31. Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res. 2016 09; 40(9):1935-44.
    View in: PubMed
    Score: 0.015
  32. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996 Mar; 53(3):225-31.
    View in: PubMed
    Score: 0.015
  33. Alcohol-related seizures and the kindling effect of repeated detoxifications: the influence of cocaine. Alcohol Alcohol. 1996 Mar; 31(2):135-43.
    View in: PubMed
    Score: 0.015
  34. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb; 19(1):92-9.
    View in: PubMed
    Score: 0.014
  35. Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. Alcohol Clin Exp Res. 2014 Nov; 38(11):2826-34.
    View in: PubMed
    Score: 0.014
  36. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. J Stud Alcohol Drugs. 2014 Mar; 75(2):335-46.
    View in: PubMed
    Score: 0.013
  37. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb; 38(2):511-20.
    View in: PubMed
    Score: 0.012
  38. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. Drug Alcohol Depend. 2013 Sep 01; 132(1-2):244-50.
    View in: PubMed
    Score: 0.012
  39. Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl). 2013 Jun; 227(4):627-37.
    View in: PubMed
    Score: 0.012
  40. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov; 18(6):937-46.
    View in: PubMed
    Score: 0.012
  41. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology. 2013 Feb; 38(3):414-22.
    View in: PubMed
    Score: 0.012
  42. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep; 33(9):1582-8.
    View in: PubMed
    Score: 0.009
  43. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res. 2009 Mar; 33(3):383-93.
    View in: PubMed
    Score: 0.009
  44. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008 Jun 09; 168(11):1188-99.
    View in: PubMed
    Score: 0.009
  45. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs. 2008 Jan; 69(1):5-13.
    View in: PubMed
    Score: 0.008
  46. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007 Nov; 31(11):1780-7.
    View in: PubMed
    Score: 0.008
  47. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
    View in: PubMed
    Score: 0.008
  48. Revealing alcohol abuse: to ask or to test? Alcohol Clin Exp Res. 2005 Jul; 29(7):1257-63.
    View in: PubMed
    Score: 0.007
  49. Measurement and choice of drinking outcome variables in the COMBINE Study. J Stud Alcohol Suppl. 2005 Jul; (15):104-9; discussion 92-3.
    View in: PubMed
    Score: 0.007
  50. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005 Mar; 29(3):395-401.
    View in: PubMed
    Score: 0.007
  51. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003 Dec; 23(6):553-62.
    View in: PubMed
    Score: 0.006
  52. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000 Nov-Dec; 35(6):587-93.
    View in: PubMed
    Score: 0.005
  53. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
    View in: PubMed
    Score: 0.003
  54. Carbohydrate-deficient transferrin as a measure of immoderate drinking: remaining issues. Alcohol Clin Exp Res. 1994 Aug; 18(4):799-812.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.